We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: Use Risk-Based Assessments for Therapeutic Protein Products
FDA: Use Risk-Based Assessments for Therapeutic Protein Products
February 27, 2013
Manufacturers and clinical investigators developing therapeutic protein products, such as monoclonal antibody cancer drugs, are urged to adopt risk-based assessments of patient immune responses that could impair drug safety and efficacy, FDA draft guidance states.